Published in final edited form as:

Angew Chem Int Ed Engl. 2010 November 8; 49(46): 8682–8685. doi:10.1002/anie.201003361.

Temporary Restraints to Overcome Steric Obstacles—Efficient Strategy for the Synthesis of Mycalamide B**

John C. Jewett and Viresh H. Rawal*

Department of Chemistry, The University of Chicago, 5735 South Ellis Avenue, Chicago, IL 60637 (USA)

Abstract

Restrain and Release: An efficient synthesis of mycalamide B is reported. The synthetic route features (a) a one-pot Mukaiyama–Michael/epoxidation sequence to introduce three of the stereocenters found in the natural product, (b) an intramolecular isocyanate trapping to produce a rigid 10-membered cyclic carbamate, and (c) the selective opening of the cyclic carbamate to reveal the fully constructed natural product.

Keywords

amide coupling; Mukaiyama–Michael; Hetero-Diels–Alder; Diastereoselective; Natural products

A fundamental concept in synthesis planning is that of convergency. Rather than the incremental, step-by-step assembly of a linear synthesis, a convergent route involves the assembly of two or more advanced fragments of a molecule in a key step, thereby reducing the arduousness of the exercise. While desirable in principle, a convergent path does not guarantee success. The steric bulk associated with advanced fragments can frustrate established reactions and thwart the coupling step. Described below is a convergent synthesis of mycalamide B, wherein steric hurdles are overcome through the use of “chemical handcuffs” to temporarily restrain portions of a molecule, thereby enabling a coupling reaction that would otherwise fail.^[1] The present work also demonstrates the successful expansion of our route for pederamine, the right-hand part of pederin, to the more-oxygenated mycalamine system.

Sponges of the genus *Mycale* have yielded a diverse group of intricate bioactive natural products.^[2] Noteworthy among these are the mycalamides, highly cytotoxic substances that are members of the pederin family of compounds.^[3] Mycalamide B, for example, displays 0.6 nM and 1.3 nM antiproliferative activity against A549 and P388 cancer cell lines, respectively.^[4,5] Given their potent anticancer activities, research groups from around the world have pursued the chemical synthesis of the mycalamides and related natural products, and impressive successes have been recorded.^[6,7,8] Although creative routes have been

[**] Generous financial support from the National Cancer Institute of the NIH (R01 CA101438) is gratefully acknowledged.

*Fax: (+) 773-702-0805, vrawal@uchicago.edu, Homepage: <http://rawalgroup.uchicago.edu>.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.

developed for synthesis of the two halves of these molecules—the pederic acid and the trioxadecalin parts—*no solution has yet been developed for the stereocontrolled coupling of the two fully-elaborated halves of mycalamides*. At the heart of the problem is that free mycalamine (**3**) readily epimerizes under acidic, basic and neutral conditions, eroding the stereochemical information at C10 (Scheme 1), such that acylation of a free mycalamine component with a pederic acid derivative proceeds with at best modest selectivity.^[9] On the other hand, acylation of a carbamate protected mycalamine unit (e.g., **4**) can be accomplished in a stereocontrolled manner, but only with simpler electrophiles, not with the fully elaborated pederic acid unit.^[10] A solution to this coupling difficulty would allow a truly convergent synthesis of the natural product and open up the possibility of concise, stereocontrolled syntheses of many members of the family as well as their analogs.

The route we envisioned for the synthesis of mycalamide B hinged on two key transformations: (a) the conversion of dihydropyranone **7** to the highly functionalized trioxadecalin framework of the mycalamine unit (Scheme 2) and (b) the stereocontrolled coupling of mycalamine unit **4**, or a derivative thereof, with a pederic acid component (**2**) (Scheme 1). The successful realization of these two transformations was expected to provide a route to mycalamide B that would be significantly shorter than those reported previously. A solution to the first of these processes was incorporated in the design of our pederin synthesis, but that for the second process was not evident at the outset.^[8c] Specifically, the Mukaiyama–Michael reaction of an appropriately substituted ketene-acetal with dihydropyranone **7** was expected to give silylenol ether **6**, the epoxidation and further elaboration of which would pave the way to mycalamine unit **5**. An efficient strategy to **5** was expected to provide ample material for overcoming the acylative-coupling hurdle.

The required dihydropyranone was synthesized in five steps from commercially available benzyl-(*S*)-glycidyl ether, **8** (Scheme 3). Vinyl cuprate addition to **8**, protection of the free hydroxyl with TIPSCl, and a Johnson–Lemieux oxidative cleavage of the vinyl unit provided aldehyde **9**. The formal hetero-Diels–Alder reaction between aldehyde **9** and Danishefsky-type diene **10** was promoted using Yamamoto’s MAD Lewis acid in conjunction with TMSOTf and afforded the expected dihydropyranone in good yield and with high diastereoselectivity.^[11,12,13] Quenching the reaction mixture with aqueous acid directly gave the free alcohol, which was methylated in a separate step to furnish dihydropyranone **11**.

Further elaboration of dihydropyranone **11** to the densely functionalized mycalamine core was achieved in a highly efficient manner and with good diastereoselectivity. Initial studies showed that the Mukaiyama–Michael reaction of MOM protected silylketeneacetal **12**^[14] with dihydropyranone **11** proceeded in 5 min at –78 °C using TBSOTf as a catalyst. However, the expected silylenol ether product (cf. **6**) was accompanied by significant amounts of the corresponding ketone. After some experimentation, it was found that rather than isolating the intermediate enol ether, it could be epoxidized in situ to afford silylepoxide **13** in good yield and high diastereoselectivity (Scheme 4). Interestingly, the epoxide was sufficiently stable so as to allow its purification by chromatography. This one synthetic operation set four new stereocenters, three of which are retained in the final product, and installed most of the required parts of mycalamine. Silylepoxide **13** was treated

with P₂O₅ in dimethoxymethane and acetonitrile to arrive at trioxadecalin **14**, the X-ray structure of which confirmed the arrangement of all the newly introduced stereocenters relative to the enantiomerically pure starting material, **8**.^[15,16]

The next hurdle that had to be crossed before arriving at the coupling precursor was reduction and methylation of the C13 ketone. Selective reduction of the ketone was expected to be challenging based on consideration of the steric and electronic factors in the two interconverting chair-chair conformations of **14**. Indeed, borohydride reduction proceeded with complete selectivity for the undesired diastereomer. On the other hand, Meerwein–Ponndorf–Verley (MPV) reduction, carried out by gently heating the reaction mixture, gave the desired alcohol as the only diastereomer, albeit as the isopropyl ester (Scheme 5).^[17] Methylation of the alcohol had to be carried out under neutral conditions using silver oxide in methyl iodide to avoid epimerization of the C10 stereocenter.^[18] In preparation for the key coupling step, the ester was hydrolyzed and the resulting acid was transformed by the Curtius rearrangement and trapping to Teoc-protected mycalamine unit **16**. Disappointingly, but in accord with earlier reports,^[6c] all attempts to acylate **16** with pederic acid chloride (**2b**) proved unsuccessful. The failure of this acylation step stands in contrast to the analogous acylation used successfully in our synthesis of pederin.^[8c]

Our analysis of the above problem and a possible solution are illustrated in Figure 1. In both pederamine and mycalamine, the dialkoxypropyl “arm” is expected to be oriented toward the pyran oxygen, so as to avoid the gemdimethyl group. However, whereas the deprotonated nitrogen in pederamine can freely rotate away from the blocking “arm” into an orientation that allows acylation, the mycalamine nitrogen is locked by the dioxane ring. Conceptually, if the “arm” could be constrained—handcuffed—to the amine, then the nitrogen would be forced to point out, making it accessible to the acylating agent. The plan was to tie the nitrogen to the interfering propyl side-chain through a 10-membered cyclic carbamate linkage. In addition to restraining the molecule, the cyclic carbamate would protect both the amine and the alcohol, and increase the acidity of the former for the acylation step.^[19] Not only are such cyclic carbamates uncommon, but the desired compound is also quite rigid and, ignoring the dioxane ring, represents an example of a system having “inside-outside” stereoisomerism.^[20]

The above concerns notwithstanding, synthesis of the cyclic carbamate proved straightforward (Scheme 6). Hydrogenolysis over palladium hydroxide on carbon cleanly removed the benzyl group from the C18 hydroxyl. Saponification of the ester followed by treatment with diphenylphosphoryl azide (DPPA) and triethylamine provided the acyl azide, which upon heating underwent the Curtius rearrangement.^[21] The resulting isocyanate was intercepted intramolecularly by the primary alcohol to provide cleanly the sought-after cyclic carbamate. To the best of our knowledge this is the first 10-membered cyclic carbamate employed in an organic synthesis exercise.

With tricycle **17** in hand, we turned our attention to its coupling with pederic acid. We were delighted to find that deprotonation of **17** with LiHMDS followed by acylation with pederic acid chloride **2b** gave the desired product, **19** (Scheme 6). The success of the acylation confirmed our hypothesis that the cyclic carbamate would overcome the steric issues

encountered by us and others and, *for the first time, allowed access to the full mycalamide framework with complete control of the aminor stereocenter*. Although the coupling reaction was an important step towards the natural product, we were not yet out of the woods. Critical to completing the synthesis was selective hydrolytic cleavage of the carbamate unit over the amide. Hydrolysis of the latter would separate the two units that had been assembled so painstakingly. Consideration of known reactivity patterns did not provide clear direction on the relative electrophilicity of the two carbonyl groups toward nucleophiles, although the amide carbonyl was expected to be more reactive. For example, *N*-acyloxazolidinones are known to react primarily at the amide carbonyl, although the steric environment around the amide carbonyl can reverse the expected chemoselectivity.^[22] Examination of the molecular model of **19** showed the carbamate carbonyl to be constrained and sterically more accessible to nucleophilic attack than the amide carbonyl. Additionally, the C7 hydroxyl group resulting from hydrolysis of the benzoate group was expected to favor the desired pathway through intramolecular addition and trans-acylation to the carbamate carbonyl. Indeed, we found that upon treatment with lithium hydroxide in the presence of lithium chloride in methanol removal of the benzoyl group and opening of the carbamate occurred, giving us mycalamide B (**1**) with a small amount of **17** recovered.^[23]

To summarize, we have developed a stereocontrolled synthesis of mycalamide B, the cornerstone of which is the use of temporary restraints to enable coupling of the fully elaborated mycalamine and pederic acid units. The total synthesis requires 14 steps from commercially available starting materials for the longest linear sequence and proceeds in 2.6% overall yield. In addition, the synthetic route features (a) a one-pot Mukaiyama–Michael/epoxidation sequence to introduce three new stereocenters found in the natural product, (b) the intramolecular trapping of the isocyanate from a Curtius rearrangement to produce a rigid, bridged 10-membered cyclic carbamate, and (c) the selective opening of the cyclic carbamate over hydrolysis of the amide linkage. The present strategy is expected to enable the synthesis of other members of this large family of highly cytotoxic natural products well as provide rapid access to significant quantities of these compounds for biological and target identification studies.

References

1. For a general discussion of strategy in total synthesis, see: Corey EJ, Cheng X-M. *The Logic of Chemical Synthesis*. 1995 New York, NY (USA) John Wiley & Sons, Inc. Nicolaou KC, Sorensen EJ. *Classics in Total Synthesis: Targets, Strategies, Methods*. 1996 New York, NY (USA) VCH Publishers, Inc. Hudlicky T, Reed JW. *The Way of Synthesis: Evolution of Design and Methods for Natural Products*. 2007 KGaA, Weinheim (Germany) Wiley-VCH Verlag GmbH & Co.
2. Peloruside A: West LM, Northcote PT. *J. Org. Chem.* 2000; 65:445–449. [PubMed: 10813954] pateamine: Northcote PT, Blunt JW, Munro MHG. *Tetrahedron Lett.* 1991; 32:6411–6414. 13-Deoxytedanolide: Fusetani N, Sugawara T, Matsunaga S, Hirota H. *J. Org. Chem.* 1991; 56:4971–4974.
3. a) Review: Narquizian R, Kocienski PJ, Mulzer J, Bohlmann R. *The Role of Natural products in Drug Discovery*. 2000 New York Springer:25–56. Piel J, Butzke D, Fusetani N, Hui D, Platzer M, Wen G, Matsunaga S. *J. Nat. Prod.* 2005; 68:472–479. [PubMed: 15787465]
4. a) Perry NB, Blunt JW, Munro MHG, Pannell LK. *J. Am. Chem. Soc.* 1988; 110:4850–4851. b) Perry NB, Blunt JW, Munro MHG, Thompson AM. *J. Org. Chem.* 1990; 55:223–227.

5. Burres NS, Clement JJ. *Cancer Res.* 1989; 49:2935–2940. [PubMed: 2720652]
6. Mycalamide A: Hong CY, Kishi Y. *J. Org. Chem.* 1990; 55:4242–4245. Nakata T, Fukui H, Nakagawa T, Matsukura H. *Heterocycles.* 1996; 42:159–164. Roush WR, Pfeifer LA. *Org. Lett.* 2000; 2:859–862. [PubMed: 10754688] Sohn J-H, Waizumi N, Zhong HM, Rawal VH. *J. Am. Chem. Soc.* 2005; 127:7290–7291. [PubMed: 15898759] Kagawa N, Ihara M, Toyota M. *Org. Lett.* 2006; 8:875–878. [PubMed: 16494463] Formal syntheses: Nakata T, Matsukura H, Jian D, Nagashima H. *Tetrahedron Lett.* 1994; 35:8229–8232. Trost BM, Yang H, Probst GD. *J. Am. Chem. Soc.* 2004; 126:48–49. [PubMed: 14709053]
7. The only previously reported total syntheses of mycalamide B are by a) Kishi, as described in reference 6a, and Kocienski, see: b) Kocienski PJ, Narquizian R, Raubo P, Smith C, Boyle FT. *Synlett.* 1998:869–872. Kocienski PJ, Narquizian R, Raubo P, Smith C, Farrugia LJ, Muir K, Boyle FT. *J. Chem. Soc., Perkin Trans.* 2000; 1:2357–2384.
8. Other members include a) onnamide A: Hong CY, Kishi Y. *J. Am. Chem. Soc.* 1991; 113:9693–9694. theopederin D: Green ME, Rech JC, Floreancig PE. *Angew. Chem.* 2008; 120:7427–7430. *Angew. Chem. Int. Ed.* 2008; 47:7317–7320. , and references cited therein. pederin: Jewett JC, Rawal VH. *Angew. Chem.* 2007; 119:6622–6624. *Angew. Chem. Int. Ed.* 2007; 46:6502–6504. , and references cited therein. theopederin B: Nishii Y, Higa T, Takahashi S, Nakata T. *Tetrahedron Lett.* 2009; 50:3597–3601. psymberin: Crimmins MT, Stevens JM, Schaaf GM. *Org. Lett.* 2009; 11:3990–3993. [PubMed: 19670853] , and references cited therein. For a synthesis of the non-natural, 18-O-methyl mycalamide B, see: f) Kocienski PJ, Raubo P, Davis JK, Boyle FT, Davies DE, Richter A. *J. Chem. Soc., Perkin Trans.* 1996; 1:1797–1808.
9. For examples of this coupling strategy for the trioxadecalin core see, refs. 6a,b,d, and 8a,b,d.
10. For examples of this coupling strategy for the trioxadecalin core see, refs. 6c,e, 7b,c and 8f.
11. Other Lewis acids tested gave lower selectivity with only moderately better yields and due to the difficulty of separating the diastereomers, MAD was deemed superior.
12. Oishi M, Aratake S, Yamamoto H. *J. Am. Chem. Soc.* 1998; 120:8271–8272.
13. Danishefsky S. *Acc. Chem. Res.* 1981; 14:400–406.
14. This was synthesized in an analogous fashion to the silylketene acetal used in our previous pederin synthesis (ref. 8c). See supporting information.
15. For a similar acetal formation, see ref. 7b and references cited therein.
16. The Cambridge Crystallographic Data Centre contains the supplementary X-ray data for 14 (# 778951): www.ccdc.cam.ac.uk/data_request/cif.
17. Kocienski had reported good selectivity for the MPV reduction of a similar substrate at room temperature, but noted that upon heating the reaction to push it to completion caused the selectivity to drop (see ref. 7c).
18. Greene AE, Drian CL, Crabbe P. *J. Am. Chem. Soc.* 1980; 102:7583–7584.
19. Greene, TW.; Wuts, PGM. *Protective Groups in Organic Synthesis.* Hoboken, NJ (USA): John Wiley & Sons, Inc.; 1999.
20. For a review, see: Alder RW. *Acc. Chem. Res.* 1983; 16:321–327.
21. Shioiri T, Ninomiya K, Yamada S. *J. Am. Chem. Soc.* 1972; 94:6203–6205. [PubMed: 5054412]
22. a) Evans DA, Britton TC, Ellman JA. *Tetrahedron Lett.* 1987; 28:6141–6144. b) Evans DA, Kaldor SW, Jones TK, Clardy J, Stout TJ. *J. Am. Chem. Soc.* 1990; 112:7001–7031.
23. The use of LiOH with LiCl to selectively cleave a carbamate in the presence of an amide bond has been shown in the context of carbohydrate synthesis, see: Wei P, Kerns RJ. *Tetrahedron Lett.* 2005; 46:6901–6905.

Figure 1.
The Handcuff Solution for Overcoming Steric Obstacles

Scheme 1.
Previous Coupling Approaches to Mycalamide B

Scheme 2.
Retrosynthetic Analysis of the Mycalamine Unit

Scheme 3.
Synthesis of Dihydropyranone **11**

Scheme 4.
Synthesis of the Trioxadecalin Core

Scheme 5.
Synthesis of Mycalamine Unit and Attempted Coupling

Scheme 6.
Coupling and Synthesis of Mycalamide B